Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C31H48O6.5H2O |
| Molecular Weight | 606.7856 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.O.O.C[C@@H]1[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@]3(C)[C@H]2[C@H](O)C[C@H]4\C([C@H](C[C@]34C)OC(C)=O)=C(/CCC=C(C)C)C(O)=O
InChI
InChIKey=ILJWZIXNGJYXOL-KFEPNFQESA-N
InChI=1S/C31H48O6.5H2O/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32;;;;;/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36);5*1H2/b26-20-;;;;;/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-;;;;;/m0...../s1
| Molecular Formula | C31H48O6 |
| Molecular Weight | 516.7092 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Fusidic acid is a anti-bacterial agent, initially isolated from Fusidium coccineum by Godtfredsen et al (Leo Pharma) in 1960. It is discussed that fusidic acid exerts its anti-microbial effect by inhibiting bacterial elongation factor G, thus suppressing the protein synthesis. Fusidic acid is widely used in Europe under the names Fucidin H(fusidic acid / hydrocortisone acetate), Fucidin (fusidic acid / sodium fusidate) and Fucicort (fusidic acid / betamethasone valerate) for the treatment of primary/secondary skin infections and inflammatory dermatoses.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Bacterial elongation factor G |
1.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | FUCIDIN Approved UseFor use in the treatment of primary and secondary skin infections caused by sensitive strains of Staphylococcus aureus, Streptococcusspp and Corynebacterium minutissimum. Primary skin infections that may be expected to respond to treatment with FUCIDIN OINTMENT (sodium fusidate) and CREAM (fusidic acid) include: impetigo contagiosa, erythrasma and secondary skin infections such as infected wounds and infected burns. |
|||
| Curative | FUCICORT Approved UseFUCICORT is indicated in inflammatory dermatoses where bacterial infection is present or likely to occur. Inflammatory dermatoses include atopic eczema, discoid eczema, seborrheic dermatitis, contact dermatitis, lichen simplex chronicus, psoriasis, discoid lupus erythematosus |
PubMed
| Title | Date | PubMed |
|---|---|---|
| A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. | 2014-01 |
|
| Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). | 2013-12 |
|
| A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. | 2013-11 |
|
| Fusidic acid is an effective treatment against Toxoplasma gondii and Listeria monocytogenes in vitro, but not in mice. | 2013-11 |
|
| Canine ocular thelaziosis caused by Thelazia callipaeda in Portugal. | 2013-07 |
|
| Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. | 2010-12 |
|
| Severe statin-induced rhabdomyolysis mimicking Guillain-Barré syndrome in four patients with diabetes mellitus treated with fusidic acid. | 2010-06 |
|
| Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. | 2009-04 |
|
| A case of recurrent rapidly progressive lower limb weakness. | 2008-07 |
|
| Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan. | 2008-03 |
|
| Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. | 2006-08 |
|
| Sideroblastic anaemia during fusidic acid treatment. | 2004-05 |
|
| Sideroblastic anaemia and fusidic acid. | 2003-02 |
|
| Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. | 2002-07-01 |
|
| [Cholestatic icterus induced by the administration of fusidic acid in a cirrhotic patient]. | 2002-06-29 |
|
| Hypocalcaemia during fusidic acid therapy. | 2002-02 |
|
| In vitro susceptibility of Mycobacterium tuberculosis to fusidic acid. | 2001-12 |
|
| Antimycobacterial plant terpenoids. | 2001-11 |
|
| Acute renal failure in association with fusidic acid. | 1997-06 |
|
| Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. | 1997-05 |
|
| Anti-HIV activity of dideoxynucleosides, foscarnet and fusidic acid is potentiated by human leukocyte interferon in blood-derived macrophages. | 1994-05-01 |
|
| Acute renal failure following intravenous fusidic acid. | 1993 |
|
| Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin. | 1992-08 |
|
| Comparative in-vitro activities of ten fluoroquinolones and fusidic acid against Mycobacterium spp. | 1990-09 |
|
| Susceptibility of mycobacteria to fusidic acid. | 1990-04 |
|
| Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. | 1989-01 |
|
| Suppression of HIV replication in vitro by fusidic acid parallels cell toxicity. | 1989-01 |
|
| Inhibition of HIV replication in vitro by fusidic acid. | 1987-10-10 |
|
| Fusidic acid-induced hyperbilirubinemia. | 1987-08 |
|
| Screening for new compounds with antiherpes activity. | 1984-10 |
|
| Staphylococcal septicaemia complicated by probable cloxacillin neurotoxicity and by jaundice induced by fusidic acid. | 1983-04 |
|
| Adverse reactions to intravenous administration of fusidic acid. | 1981 |
|
| Protein synthesis in Mycobacterium tuberculosis H37Rv and the effect of streptomycin in streptomycin-susceptible and -resistant strains. | 1973-09 |
|
| Haematuria during methicillin therapy. | 1971-07 |
|
| Fusidic acid: a new antibiotic. | 1962-03-10 |
Patents
Sample Use Guides
A small amount of fucidin ointment(sodium fusidate) or cream (fusidic acid) should be
applied to the lesion 3 or 4 times daily until favourable results are achieved. Futicort cream (fusidic acid / betamethasone valerate) is applied 2 times daily.
Route of Administration:
Topical
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:42:47 GMT 2025
by
admin
on
Mon Mar 31 19:42:47 GMT 2025
|
| Record UNII |
7EB01222KN
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000087312
Created by
admin on Mon Mar 31 19:42:47 GMT 2025 , Edited by admin on Mon Mar 31 19:42:47 GMT 2025
|
PRIMARY | |||
|
SUB20997
Created by
admin on Mon Mar 31 19:42:47 GMT 2025 , Edited by admin on Mon Mar 31 19:42:47 GMT 2025
|
PRIMARY | |||
|
7EB01222KN
Created by
admin on Mon Mar 31 19:42:47 GMT 2025 , Edited by admin on Mon Mar 31 19:42:47 GMT 2025
|
PRIMARY | |||
|
76957416
Created by
admin on Mon Mar 31 19:42:47 GMT 2025 , Edited by admin on Mon Mar 31 19:42:47 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |